SUSTIVA
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
SUSTIVA by Bristol Myers Squibb is [see clinical pharmacology ]. Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection. First approved in 1998.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTIVA is an oral capsule small-molecule NDA approved by Bristol Myers Squibb in 1998. The exact mechanism of action and indication are not specified in available data, but the product represents a foundational therapeutic from the late 1990s era. As a non-biologic agent, it targets a specific molecular pathway relevant to its approved indication.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential for transition planning and smaller, specialized commercial teams.
Mechanism of Action
[see Clinical Pharmacology ].
Worked on SUSTIVA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.